Overview of Gene Therapy Clinical Studies for BAG3-DCM
Date: April 15, 2026
Time: 6:00pm EDT
Rocket Pharmaceuticals will provide high-level overviews of clinical trials and adeno-associated virus (AAV) gene therapy for BAG3 cardiomyopathy. Dr. Kasetty will also present more detailed information on RP-A701 BAG3 Gene Therapy.
The RP-A701 BAG3 Gene Therapy is an investigational gene therapy being developed specifically for people with dilated cardiomyopathy caused by a BAG3 mutation. The investigational therapy is designed to deliver a working copy of the BAG3 gene to heart muscle cells, with the goal of helping those cells produce the BAG3 protein at more typical levels. By addressing the underlying genetic cause of the disease, this investigational approach is intended to support healthier heart cell function and slow or stabilize disease progression.
Presenter: Mayur Kasetty, MD, Associate Vice President, AAV Global Program Head
Understanding Wearables, Heart Data, and the OCORO Heart Study
Date: May 20, 2026
Time: 6:00pm EDT
Join us for an educational webinar about wearable devices, heart data, and what these tools may help us learn about living with a heart condition. We’ll talk about what devices are currently being used and what types of data that they collect.
We’ll also share an overview of the OCORO Heart Study, a remote research study for people living with heart conditions. The goal of the study is to help researchers better understand how heart conditions change over time in real life. Participation is done from home, and the study is observational only, meaning there are no drugs, procedures, or clinic visits involved. We’ll explain what taking part may look like, who may be eligible, and how to learn more.
Presenter: Greg Kurio, MD, Cardiologist and Principal Investigator, OCORO Heart Study